Shopping Cart 0
Cart Subtotal
AED 0

BIND Therapeutics Inc (BIND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

BIND Therapeutics Inc (BIND Therapeutics) is a nanomedicine platform company that develops and commercializes preclinical candidates for cardiovascular disease, cancer and inflammatory disease. The company's pipeline products include BIND-014, an Accurin that contains the well-established chemotherapeutic agent, docetaxel. It provides AZD-2811, targeted kinase inhibitor, bind-267, and bind-787. BIND Therapeutics also develops oligonucleotides, immuno-oncology, tam targeting, and GC-C. BIND Therapeutic's medicinal nanoengineering platform overcomes this limitation by adding unprecedented ability to enhance the trafficking of drugs to tumors, while minimizing exposure of healthy tissues. The company operates through its office located in Russia. BIND Therapeutics is headquartered in Cambridge, Massachusetts, the US.

BIND Therapeutics Inc (BIND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

BIND Therapeutics Secures USD15 Million from Hercules Technology 14

Bind Biosciences Raises USD8.7 Million In Venture Financing 14

Bind Biosciences Secures USD35 Million In Series D Financing Round 15

BIND Biosciences Secures USD4.7 Million In Venture Financing 17

Partnerships 18

BIND Therapeutics Enters Into Licensing Agreement with Yale University 18

BIND Therapeutics Forms Partnership with Affilogic 18

PeptiDream Enters into Research Agreement with BIND Therapeutics 19

Bind Therapeutics and Synergy Pharma Enter into Research Agreement 20

BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 21

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 21

Bind Therapeutics Enters into R&D Agreement with Merck 22

Bind Therapeutics Enters into Research Agreement with Roche for Accurins 23

Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 24

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 25

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 26

Licensing Agreements 27

Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 27

Equity Offering 28

BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 28

Bind Therapeutics Completes IPO For USD70.5 Million 30

Asset Transactions 31

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 31

BIND Therapeutics Inc-Key Competitors 33

Key Employees 34

Locations And Subsidiaries 35

Head Office 35

Recent Developments 36

Financial Announcements 36

May 09, 2016: BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update 36

Mar 15, 2016: BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS Platform 38

Corporate Communications 40

Jun 17, 2016: BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners 40

May 02, 2016: BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11


List Of Table

List of Tables

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BIND Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

BIND Therapeutics Secures USD15 Million from Hercules Technology 14

Bind Biosciences Raises USD8.7 Million In Venture Financing 14

Bind Biosciences Secures USD35 Million In Series D Financing Round 15

BIND Biosciences Secures USD4.7 Million In Venture Financing 17

BIND Therapeutics Enters Into Licensing Agreement with Yale University 18

BIND Therapeutics Forms Partnership with Affilogic 18

PeptiDream Enters into Research Agreement with BIND Therapeutics 19

Bind Therapeutics and Synergy Pharma Enter into Research Agreement 20

BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 21

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 21

Bind Therapeutics Enters into R&D Agreement with Merck 22

Bind Therapeutics Enters into Research Agreement with Roche for Accurins 23

Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 24

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 25

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 26

Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 27

BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 28

Bind Therapeutics Completes IPO For USD70.5 Million 30

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 31

BIND Therapeutics Inc, Key Competitors 33

BIND Therapeutics Inc, Key Employees 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

BIND Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

BIND Therapeutics Inc (BIND Therapeutics) is a nanomedicine platform company that develops and commercializes preclinical candidates for cardiovascular disease, cancer and inflammatory disease. The company's pipeline products include BIND-014, an Accurin that contains the well-established chemotherapeutic agent, docetaxel. It provides AZD-2811, targeted kinase inhibitor, bind-267, and bind-787. BIND Therapeutics also develops oligonucleotides, immuno-oncology, tam targeting, and GC-C. BIND Therapeutic's medicinal nanoengineering platform overcomes this limitation by adding unprecedented ability to enhance the trafficking of drugs to tumors, while minimizing exposure of healthy tissues. The company operates through its office located in Russia. BIND Therapeutics is headquartered in Cambridge, Massachusetts, the US.

BIND Therapeutics Inc (BIND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

BIND Therapeutics Secures USD15 Million from Hercules Technology 14

Bind Biosciences Raises USD8.7 Million In Venture Financing 14

Bind Biosciences Secures USD35 Million In Series D Financing Round 15

BIND Biosciences Secures USD4.7 Million In Venture Financing 17

Partnerships 18

BIND Therapeutics Enters Into Licensing Agreement with Yale University 18

BIND Therapeutics Forms Partnership with Affilogic 18

PeptiDream Enters into Research Agreement with BIND Therapeutics 19

Bind Therapeutics and Synergy Pharma Enter into Research Agreement 20

BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 21

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 21

Bind Therapeutics Enters into R&D Agreement with Merck 22

Bind Therapeutics Enters into Research Agreement with Roche for Accurins 23

Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 24

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 25

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 26

Licensing Agreements 27

Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 27

Equity Offering 28

BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 28

Bind Therapeutics Completes IPO For USD70.5 Million 30

Asset Transactions 31

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 31

BIND Therapeutics Inc-Key Competitors 33

Key Employees 34

Locations And Subsidiaries 35

Head Office 35

Recent Developments 36

Financial Announcements 36

May 09, 2016: BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update 36

Mar 15, 2016: BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS Platform 38

Corporate Communications 40

Jun 17, 2016: BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners 40

May 02, 2016: BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11


List Of Table

List of Tables

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BIND Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11

BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

BIND Therapeutics Secures USD15 Million from Hercules Technology 14

Bind Biosciences Raises USD8.7 Million In Venture Financing 14

Bind Biosciences Secures USD35 Million In Series D Financing Round 15

BIND Biosciences Secures USD4.7 Million In Venture Financing 17

BIND Therapeutics Enters Into Licensing Agreement with Yale University 18

BIND Therapeutics Forms Partnership with Affilogic 18

PeptiDream Enters into Research Agreement with BIND Therapeutics 19

Bind Therapeutics and Synergy Pharma Enter into Research Agreement 20

BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 21

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 21

Bind Therapeutics Enters into R&D Agreement with Merck 22

Bind Therapeutics Enters into Research Agreement with Roche for Accurins 23

Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 24

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 25

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 26

Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 27

BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 28

Bind Therapeutics Completes IPO For USD70.5 Million 30

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 31

BIND Therapeutics Inc, Key Competitors 33

BIND Therapeutics Inc, Key Employees 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

BIND Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.